Product image of Metocard Zk (Metoprolol Succinate) supplied by GNH India

Metocard Zk

Active Ingredient:
Metoprolol Succinate
Origin:
EU

Metocard Zk (Metoprolol Succinate)

Metoprolol Succinate, the active ingredient in Metocard Zk, is a beta blocker presented as an oral dosage form for oral use. It is employed to manage high blood pressure, relieve chronic stable angina, improve outcomes in heart failure with reduced ejection fraction, and reduce risk after myocardial infarction.

GNH India supplies Metocard Zk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for cardiovascular therapies.

Manufacturer / TM Owner

Zaklady Farmaceutyczne Polpharma S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Metoprolol Succinate is a selective β1‑adrenergic blocker used in cardiovascular disease management.
  • Hypertension: lowers blood pressure by reducing cardiac output and renin release.
  • Chronic stable angina: decreases myocardial oxygen demand, relieving chest pain.
  • Heart failure (reduced ejection fraction): improves survival and reduces hospitalizations.
  • Post‑myocardial infarction: lowers risk of recurrent events and improves cardiac remodeling.
  • Atrial fibrillation (rate control): helps maintain an appropriate ventricular rate.

How It Works

  • Metoprolol Succinate selectively antagonizes β1‑adrenergic receptors in cardiac tissue, blocking the effects of endogenous catecholamines such as norepinephrine. This reduces heart rate, myocardial contractility, and conduction velocity, leading to decreased cardiac output and lower myocardial oxygen consumption. The sustained‑release formulation provides consistent plasma concentrations over 24 hours, supporting stable hemodynamic control.

Side Effects

Metoprolol Succinate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Fatigue or tiredness
  • Dizziness or light‑headedness
  • Cold extremities (hands/feet)
  • Gastrointestinal upset (nausea, abdominal discomfort)
  • Sleep disturbances (insomnia or vivid dreams)

Serious or Rare Side Effects

  • Bradycardia (excessively low heart rate)
  • Hypotension (significant blood pressure drop)
  • Heart block or atrioventricular conduction disturbances
  • Worsening heart failure symptoms
  • Severe bronchospasm in patients with asthma
  • Depression or mood changes

Precautions & Warnings

When prescribing Metoprolol Succinate, clinicians should consider several safety precautions to minimize risk.

  • Assess baseline heart rate and blood pressure: avoid use in patients with severe bradycardia or hypotension.
  • Review respiratory status: use cautiously in patients with asthma or chronic obstructive pulmonary disease.
  • Monitor renal and hepatic function: dose adjustments may be needed in impairment.
  • Evaluate for diabetes: may mask hypoglycemia symptoms.
  • Counsel patients on gradual dose changes: abrupt discontinuation can precipitate rebound tachycardia or hypertension.
  • Store at ambient temperature below 25 °C: keep in original packaging, protect from moisture and light.

Avoid Interactions

Metoprolol Succinate can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

  • Non‑selective β‑blockers or other β‑blocker agents: additive bradycardia and hypotension.
  • Calcium channel blockers (verapamil, diltiazem): increased risk of heart block and severe hypotension.
  • Antihypertensive agents (ACE inhibitors, ARBs, diuretics): may cause excessive blood pressure lowering.

Moderate Interactions (Monitor Closely)

  • Antidiabetic drugs (insulin, sulfonylureas): may mask hypoglycemia signs.
  • CNS depressants (sedatives, opioids): enhanced dizziness or fatigue.
  • Antidepressants (SSRIs, tricyclics): possible alterations in plasma levels.

Frequently Asked Questions

Metocard Zk contains Metoprolol Succinate, a selective β1‑adrenergic blocker that is prescribed for hypertension, chronic stable angina, heart failure with reduced ejection fraction, and for secondary prevention after a myocardial infarction. These indications reflect its ability to lower heart rate, reduce myocardial oxygen demand, and improve cardiac efficiency.

Metoprolol Succinate works by selectively blocking β1‑adrenergic receptors in the heart. This antagonism reduces the effects of catecholamines such as norepinephrine, leading to a slower heart rate, decreased contractile force, and lower cardiac output, which together help control blood pressure and lessen the workload on the heart.

The dosage of Metocard Zk is individualized by the prescribing clinician based on the patient’s specific condition, response, and tolerability. The prescriber determines the appropriate strength, frequency, and titration schedule, and adjustments are made according to clinical monitoring.

The safety of Metocard Zk in pregnancy and lactation has not been definitively established. It is generally classified as contraindicated or used only when the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider before use.

To order Metocard Zk, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details, and any necessary import documentation.

Metocard Zk (Metoprolol Succinate) is a β1‑selective blocker, offering cardiac‑focused effects with fewer bronchial side effects compared with non‑selective agents like propranolol. Its extended‑release formulation provides once‑daily dosing and more stable plasma levels, which can improve adherence relative to short‑acting beta blockers.

Metocard Zk should be stored at ambient temperature below 25 °C, protected from moisture and direct light. Keep the tablets in the original container until use, and avoid exposing them to high humidity or extreme temperatures to maintain potency.

Metocard Zk is taken orally, usually as a whole tablet swallowed with water. It is commonly prescribed for once‑daily dosing due to its extended‑release formulation, but the exact schedule is set by the prescribing clinician based on therapeutic goals.

Serious risks include severe bradycardia, marked hypotension, heart block, worsening heart failure, and bronchospasm in patients with underlying asthma or COPD. Patients should be monitored for these events, especially during dose initiation or when combined with other cardiovascular agents.

Metocard Zk is contraindicated in patients with known hypersensitivity to metoprolol or other beta blockers, those with severe bradycardia (heart rate <50 bpm), second‑ or third‑degree atrioventricular block without a pacemaker, and individuals with uncompensated heart failure or cardiogenic shock.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metoprolol Succinate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT